Download Files:
AXL-IN-13
$875 – $4,590
Products Details
Product Description
– AXL-IN-13 is a potent and orally active AXL inhibitor (IC50: 1.6 nM, Kd: 0.26 nM). AXL-IN-13 reverses TGF-β1-induced epithelial-mesenchymal transition (EMT), and inhibits cancer cell migration and invasion[1].
Web ID
– HY-151904
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C34H41FN6O5
References
– [1]Chan S, et al. Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors. J Med Chem. 2022 Nov 24;65(22):15374-15390.
CAS Number
– 2376928-82-2
Molecular Weight
– 632.72
Compound Purity
– 98.03
SMILES
– COC1=C(C=C(C2=C1)N=CC=C2OC3=C(C=C(C=C3)NC4=NN(C=C4C(NC5CCCCC5)=O)C)F)OCCCN6CCOCC6
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– FLT3;PDGFR;TAM Receptor
Isoform
– PDGFRβ
Pathway
– Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
